Overview
- Preliminary 2025 total global revenue was approximately $616 million, including Briumvi U.S. net product revenue of about $594 million and $182 million in Q4.
- Guidance for 2026 targets total global revenue of $875 million to $900 million, with Briumvi U.S. expected at $825 million to $850 million.
- TG Therapeutics forecasts roughly $350 million in 2026 operating expenses excluding non-cash compensation, plus about $100 million tied to subcutaneous Briumvi inventory build and a secondary manufacturer.
- Planned 2026 readouts include mid-year ENHANCE topline on consolidated IV dosing, preliminary Phase 1 azer-cel data in progressive MS in the second half, and subcutaneous Briumvi topline around year-end 2026 or early 2027.
- Shares rose in extended and next-day trading after the update, though third-party technicals still indicate a bearish trend, and the reported figures remain unaudited.